Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver

References

• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, And outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in The United States and Europe. Hepatology. 2016;64(5):1577–1586. doi:10.1002/hep.28785
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, Predictions, Risk Factors and Prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: growing Impact of NAFLD. Hepatology. 2020;72(5):1605–1616. doi:10.1002/hep.31173
   PubMed Web of Science ®Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9
   PubMed Web of Science ®Google Scholar
• Loomba R, Sanyal AJ. The Global NAFLD Epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686–690. doi:10.1038/nrgastro.2013.171
   PubMed Web of Science ®Google Scholar
• Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842–845. doi:10.1016/s0016-5085(98)70599-2
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of Non-alcoholic fatty liver disease (NAFLD). Metabolism: Clinical and Experimental. 2016;65(8):1038–1048. doi:10.1016/j.metabol.2015.12.012
   PubMed Web of Science ®Google Scholar
• Gentilini A, Caligiuri A, Marra F. Molecular Pathogenesis of NASH. Int J Mol Sci. 2016;17(9):1575. doi:10.3390/IJMS17091575
   PubMed Web of Science ®Google Scholar
• Prabhudas M, Bowdish D, Drickamer K, et al. Standardization of Scavenger receptor nomenclature. J Immunol. 2014;192(5):1997–2006. doi:10.4049/jimmunol.1490003
   PubMed Web of Science ®Google Scholar
• Pepino MY, Kuda O, Samovski D. Structure- Function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr. 2014;34:1–303. doi:10.1146/annurev-nutr-071812-161220
   PubMed Web of Science ®Google Scholar
• Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis. Sci Signal. 2009;2(72):re3. doi:10.1126/scisignal.272re3
   PubMed Web of Science ®Google Scholar
• He J, Lee JH, Febbraio M, Xie W. The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Biol Med. 2011;236(10):1116–1121. doi:10.1258/ebm.2011.011128
   Google Scholar
• Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR. Gastroenterology. 2008;134(2):556–567. doi:10.1053/j.gastro.2007.11.037
   PubMed Web of Science ®Google Scholar
• Garcia-monzon C, Lo Iacono O, Crespo J. Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. Eur J Clin Invest. 2014;44(1):65–73. doi:10.1111/eci.12192
   PubMed Web of Science ®Google Scholar
• Greco D, Kotronen A, Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. 2008;2(5):294 G1281–G1287. doi:10.1152/ajpgi.00074.2008
   Web of Science ®Google Scholar
• Febbraio M, Abumrad NA, Hajjar DP. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999;274(27):19055–19062. doi:10.1074/JBC274.27.19055
   PubMed Web of Science ®Google Scholar
• Karunakaran U, Elumalai S, Moon JS, Won KC. CD36 Signal Transduction in Metabolic Diseases: novel Insights and Therapeutic Targeting. Cells. 2021;10(7):1833. doi:10.3390/cells10071833
   PubMed Web of Science ®Google Scholar
• Miquilena-Colina ME, Lima-Cabello E, Sanchez-Campos S, et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, Hyperinsulinaemia and increased Steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut. 2011;60(10):1394–1402. doi:10.1136/gut.2010.222844
   PubMed Web of Science ®Google Scholar
• Heebøll S, Poulsen MK, Ornstrup MJ, et al. Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls. Int J Obes. 2017;41(2):262–267. doi:10.1038/ijo.2016.223
   Web of Science ®Google Scholar
• Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53(3):362–376. doi:10.1007/s00535-017-1415-1
   PubMed Web of Science ®Google Scholar
• Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and Its Management. Nutr Clin Pract. 2020;35(1):72–84. doi:10.1002/ncp.10449
   PubMed Web of Science ®Google Scholar
• Glatz JF, Luiken JJ. From fat to FAT (CD36/SR-B2): understanding the regulation of cellular fatty acid uptake. Biochimie. 2017;136:21–26. doi:10.1016/j.biochi.2016.12.007
   PubMed Web of Science ®Google Scholar
• Luiken JJ, Chanda D, Nabben M, Neumann D, Glatz JF. Post-translational modifications of CD36 (SR-B2): expression of glycoprotein expression in the expression of anthill fatty acid uptake. Biochim Biophys Acta. 2016;1862(12):2253–2258. doi:10.1016/j.bbadis.2016.09.004
   PubMed Web of Science ®Google Scholar
• Tao N, Wagner SJ, Lublin DM. CD36 is palmitoylated on both N-and C-terminal cytoplasmic tails. J Biol Chem. 1996;271(37):22315–22320. doi:10.1074/JBC271.37.22315
   PubMed Web of Science ®Google Scholar
• Zeng S, Wu F, Chen M. Inhibition of fatty acid translocase (FAT/CD36) palmitoylation enhances hepatic fatty acid β-oxidation increasing its localization to mitochondria and interaction with long-chain acyl-CoA synthetase 1. Antioxidants & Redox Signaling. 2022;36(16–18):1081–1100. doi:10.1089/ars.2021.0157
   PubMed Web of Science ®Google Scholar
• Pohl J, Ring A, Korkmaz U, Ehehalt R, Stremmel W. FAT/CD36-mediated long-chain fatty acid uptake in adipocytes requires plasma membrane. Mol Biol Cell. 2005;16(1):24–31. doi:10.1091/MBC.E04-07-0616
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhang C, Luo X, et al. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic Steatohepatitis. J Hepatol. 2018;69(3):705–717. doi:10.1016/j.jhep.2018.04.006
   PubMed Web of Science ®Google Scholar
• Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of Lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental. 2016;65(8):1049–1061. doi:10.1016/j.metabol.2016.02.014
   PubMed Web of Science ®Google Scholar
• Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537–2564. doi:10.1016/j.cell.2021.04.015
   PubMed Web of Science ®Google Scholar
• Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68(2):280–295. doi:10.1016/j.jhep.2017.11.014
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of Follow - up. Hepatology. 2015;61(5):1547–1554. doi:10.1002/hep.27368
   PubMed Web of Science ®Google Scholar
• Geng Y, Faber KN, de Meijer VE, Blokzijl H, Moshage H. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? J Hepatol Int. 2021;15(1):21–35. doi:10.1007/s12072-020-10121-2
   PubMed Web of Science ®Google Scholar
• Gaemers IC, Stallen JM, Kunne C, et al. Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease. Biochim Biophys Acta. 2011;1812(4):447–458. doi:10.1016/j.bbadis.2011.01.003
   PubMed Web of Science ®Google Scholar
• Singh R, Kaushik S, Wang Y, et al. Autophagy regulates lipid metabolism. Nature. 2009;458(7242):1131–1135. doi:10.1038/nature07976
   PubMed Web of Science ®Google Scholar
• Ueno T, Komatsu M. Autophagy in liver: functions in health and disease. Nat Rev Gastroenterol Hepatol. 2017;14(3):170–184. doi:10.1038/nrgastro.2016.185
   PubMed Web of Science ®Google Scholar
• Qian H, Chao X, Williams J, et al. Autophagy in liver diseases: a review. Mol Aspects Med. 2021;82:100973. doi:10.1016/j.mam.2021.100973
   PubMed Web of Science ®Google Scholar
• Schulze RJ, Krueger EW, Weller SG, et al. Direct Lysosome-based autophagy of lipid caustic in hepatocytes. Proc Natl Acad Sci U S A. 2020;117(51):32443–32452. doi:10.1073/pnas.2011442117
   PubMed Web of Science ®Google Scholar
• Laker RC, Drake JC, Wilson RJ, et al. Ampk phosphorylation of Ulk1 is required for targeting of mitochondria to lysosomes in exercise-induced mitophagy. Nat Commun. 2017;8(1):548. doi:10.1038/s41467-017-00520-9
   PubMed Web of Science ®Google Scholar
• Kim J, Kim YC, Fang C, et al. Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. Cell. 2013;152(1–2):290–303. doi:10.1016/j.cell.2012.12.016
   PubMed Web of Science ®Google Scholar
• Li Y, Yang P, Zhao L, et al. CD36 plays a negative role in the regulation of lipophagy in the hepatocyte through an AMPK-dependent pathway. J Lipid Res. 2019;60(4):844–855. doi:10.1194/JLRM090969
   PubMed Web of Science ®Google Scholar
• Ameer F, Scandiuzzi L, Hasnain S, Kalbacher H, Zaidi N. De Novo lipogenesis in Health and Disease. Metabolism: Clinical and Experimental. 2014;63(7):895–902. doi:10.1016/j.metabol.2014.04.003
   PubMed Web of Science ®Google Scholar
• Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver Diseases. Gastroenterology. 2014;146(3):726–735. doi:10.1053/j.g.astro.2013.11.049
   PubMed Web of Science ®Google Scholar
• Yang P, Zeng H, Tan W, et al. Loss of CD36 impairs hepatic insulin signaling by enhancing the interaction of PTP1B with IR. FASEB J. 2020;34(4):5658–5672. doi:10.1096/fj.201902777RR
   PubMed Web of Science ®Google Scholar
• Xu D, Wang Z, Xia Y, et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. Nature. 2020;580(7804):530–535. doi:10.1038/s41586-020-2183-2
   PubMed Web of Science ®Google Scholar
• Zeng H, Qin H, Liao M, et al. CD36 Promotes de Novo Lipogenesis in the hepatocyte through Insig2-dependent SREBP1 Processing. Mol Metab. 2022;57. doi:10.1016/j.molmet.2021.101428
   PubMed Web of Science ®Google Scholar
• Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its Role in LDL metabolism. Trends Biochem Sci. 2007;32(2):71–77. doi:10.1016/j.t.bs2006.12.008
   PubMed Web of Science ®Google Scholar
• Lambert G. Unravelling the Functional Significance of PCSK9. Curr Opin Lipidol. 2007;18(3):304–309. doi:10.1097/MOL.0b013e3281338531
   PubMed Web of Science ®Google Scholar
• Demers A, Samami S, Lauzier B, et al. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes. Arterioscler Thromb Vasc Biol. 2015;35(12):2517–2525. doi:10.1161/ATVBAHA.115.306032
   PubMed Web of Science ®Google Scholar
• Lebeau PF, Byun JH, Platko K, et al. Pcsk9 Knockout Counterfeiting of diet-induced non-alcoholic steatohepatitis, Fibrosis and liver injury in mice. JHEP Rep. 2019;1(6):418–429. doi:10.1016/j.jhepr.2019.10.009
   PubMedGoogle Scholar
• Palumbo M, Giammanco A, Purrello F, et al. Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation. Front Mol Biosci. 2022;9:925587. doi:10.3389/fmolb.2022.925587
   PubMed Web of Science ®Google Scholar
• Seidah NG, Garçon D. Expanding Biology of PCSK9: roles in Atherosclerosis and Beyond. Curr Atheroscler Rep. 2022;24(1):1–10. doi:10.1007/s11883-022-01057-z
   PubMed Web of Science ®Google Scholar
• Repa JJ, Liang G, Ou J, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and lxrbeta. Genes Dev. 2000;14(22):2819–2830. doi:10.1101/gad.844900
   PubMed Web of Science ®Google Scholar
• Łtowski J. Liver X Receptors (LXRs). Part I: structure, function, regulation of activity and role in lipid metabolism. Postepy Hig Med Dosw. 2007;61:736–759.
   Google Scholar
• Wang B, Tontonoz P. Liver X receptors in lipid signalling and envelope homeostasis. Nat Rev Endocrinol. 2018;14(8):452–463. doi:10.1038/s41574-018-0037-x
   PubMed Web of Science ®Google Scholar
• Lee JH, Xie W. PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks. Mol Pharm. 2008;5(1):60–66. doi:10.1021/mp700121u
   PubMed Web of Science ®Google Scholar
• Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR. Gastroenterology. 2008;134(2):556. doi:10.1053/j.gastro.2007.11.037
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhai Y, Mu Y, et al. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic Pathway. J Biol Chem. 2006;281(21):15013–15020. doi:10.1074/JBCM511116200
   PubMed Web of Science ®Google Scholar
• Hajri T, Zaiou M, Fungwe TV, Ouguerram K, Besong S. Epigenetic Regulation of Peroxisome Proliferator-Activated Receptor Gamma Mediates High-Fat Diet-Induced Non-alcoholic Fatty Liver Disease. Cells. 2021;10(6):548. doi:10.3390/cells10061355
   PubMed Web of Science ®Google Scholar
• Hoffman EC, Reyes H, Chu FF. Cloning of a factor required for activity of the Ah (Dioxin) receptor. Science. 1991;252(5008):954–958. doi:10.1126/science.1852076
   PubMed Web of Science ®Google Scholar
• Lee JH, Wada T, Febbraio M. A novel role of dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology. 2010;139(2):653–663. doi:10.1053/j.gastro.2010.03.033
   PubMed Web of Science ®Google Scholar
• Yao L, Wang C, Zhang X, et al. Hyperhomocysteinemia activates the aryl hydrocarbon receptor/CD36 pathway to promote hepatic steatosis in Mice. Hepatology. 2016;64(1):92–105. doi:10.1002/hep.28518
   PubMed Web of Science ®Google Scholar
• Kawano Y, Nishiumi S, Tanaka S, et al. Activation of the aryl hydrocarbon receptor induces hepatic steatosis via the upregulation of fatty acid. Arch Biochem Biophys. 2010;504(2):221–227. doi:10.1016/j.abb2010.09.001
   PubMed Web of Science ®Google Scholar
• Yuan P, Dong M, Lei H, et al. Targeted metabolomics reveals that 2,3,7,8-tetrachlorodibenzofuran exposure induces hepatic steatosis in male Mice. Environ Pollut. 2020;259:113820. doi:10.1016/j.nvpol.2019.113820
   PubMed Web of Science ®Google Scholar
• Jin J, Wahlang B, Thapa M, et al. Proteomics and metabolic phenotyping define principal roles for the aryl hydrocarbon receptor in mouse Liver. Acta Pharm Sin B. 2021;11(12):3806–3819. doi:10.1016/j.aPSB2021.10.014
   PubMed Web of Science ®Google Scholar
• Suto T, Karonitsch T. The immunobiology of mTOR in autoimmunity. J Autoimmun. 2020;110:102373. doi:10.1016/j.jaut.2019.102373
   PubMed Web of Science ®Google Scholar
• Takashima M, Ogawa W, Emi A, Kasuga M. Regulation of SREBP1c expression by mTOR signaling in the hepatocyte. Kobe J Med Sci. 2009;55(2):E45–E52.
   PubMedGoogle Scholar
• Duvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39(2):171–183. doi:10.1016/j.molcel.2010.06.022
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ma KL, Ruan XZ, Liu BC. Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury. Int J Biol Sci. 2016;12(5):569–579. doi:10.7150/ijbs.14027
   PubMed Web of Science ®Google Scholar
• Tan SH, Shui G, Zhou J, et al. Critical role of SCD1 in autophagy regulation via lipogenesis and lipid rafts-coupled AKT-FOXO1 signaling Pathway. Autophagy. 2014;10(2):226–242. doi:10.4161/auto.27003
   PubMed Web of Science ®Google Scholar
• Han J, Wang Y. mTORC1 signaling in hepatic lipid metabolism. Protein Cell. 2018;9(2):145–151. doi:10.1007/s13238-017-0409-3
   PubMed Web of Science ®Google Scholar
• Wang C, Yan Y, Hu L, et al. Rapamycin-mediated CD36 translational suppression contributes to Worsting of hepatic steatosis. Biochem Biophys Res Commun. 2014;447(1):57–63. doi:10.1016/j.bBRC.2014.03.103
   PubMed Web of Science ®Google Scholar
• Wang C, Hu L, Zhao L, et al. Inflammatory stress increases hepatic CD36 translational efficiency via activation of the mTOR signalling Pathway. PLoS One. 2014;9(7):e103071. doi:10.1371/journalpone.0103071
   PubMed Web of Science ®Google Scholar
• Barroso E, Rodriguez-Rodriguez R, Zarei M, et al. SIRT3 deficiency ates fatty liver by attenuating the HIF1α -lipin 1 pathway and increasing CD36 through Nrf2. Cell Commun Signal. 2020;18(1). doi:10.1186/s12964-020-00640-8
   PubMed Web of Science ®Google Scholar
• Zhou SS, Zhang YL, Chang YS. Sheng Li Xue Bao. Sheng Li Xue Bao: [Acta Physiologica Sinica]. 2021;73(5):772–780.
   PubMedGoogle Scholar
• Shen C, Chen JH, Oh HR, Park JH. Transcription factor SOX2 contributes to nonalcoholic fatty liver disease development by regulating the Expression of the fatty acid transporter CD36. FEBS Lett. 2021;595(19):2493–2503. doi:10.1002/1873-3468.14193
   PubMed Web of Science ®Google Scholar
• Lin HY, Wang FS, Yang YL, Huang YH. MicroRNA-29a Suppresses CD36 to Ameliorate High Fat Diet-Induced Steatohepatitis and Liver Fibrosis in Mice. Cells. 2019;8(10):1298. doi:10.3390/cells8101298
   PubMed Web of Science ®Google Scholar
• Wang X, Ma Y, Yang LY, Zhao D. 20A-5P Ameliorates non-alcoholic Fatty Liver Disease via Inhibiting the Expression of CD36. Front Cell Dev Biol. 2020;8:59 6329. doi:10.3389/fcell.2020.596329
   Web of Science ®Google Scholar
• Smolka C, Schlosser D, Hohnloser C, et al. Mir-100 overexpression attenuates high fat diet induced weight gain, Liver steatosis, hypertriglyceridemia and development of metabolic syndrome in mice. Mol Med. 2021;27(1):101. doi:10.1186/S10020-021-00364-6
   PubMed Web of Science ®Google Scholar
• Wang K, Feng X, Chai L, Cao S, Qiu F. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev. 2017;49(2):139–157. doi:10.1080/03602532.2017.1306544
   PubMed Web of Science ®Google Scholar
• Yu M, Alimujiang M, Hu L, Liu F, Bao Y, Yin J. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver. Int J Biol Sci. 2021;17(7):1693–1707. doi:10.7150/iJbs.54604
   PubMed Web of Science ®Google Scholar
• Choi YJ, Lee KY, Jung SH, et al. Activation of AMPK by berberine induces hepatic lipid accumulation by upregulation of fatty acid translocase CD36 In mice. Toxicology and Applied Pharmacology. 2017;316:74–82. doi:10.1016/j.t.aap2016.12.019
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of Curcumin: problems and Promises. Mol Pharm. 2007;4(6):807–818. doi:10.1021/mp700113r
   PubMed Web of Science ®Google Scholar
• Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The Essential Medicinal Chemistry of Curcumin. J Med Chem. 2017;1(5):1620–1637. doi:10.1021/acs.Jmedchem.6b00975
   Web of Science ®Google Scholar
• Tsuda T. Curcumin as a functional food-derived factor: metabolites, bioactivity, and Future Perspectives. Food Funct. 2018;9(2):705–714. doi:10.1039/c7fo01242j
   PubMed Web of Science ®Google Scholar
• Yan C, Zhang Y, Zhang X, Aa J, Wang G, Xie Y. Curcumin regulates endogenous and Exogenous metabolism via NRF2-FXR-LXR Pathway in NAFLD mice. Biomed Pharmacother. 2018;105:274–281. doi:10.1016/j.biopha.2018.05.135
   PubMed Web of Science ®Google Scholar
• Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, Pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013;14(10):20704–20728. doi:10.3390/ijms141020704
   PubMed Web of Science ®Google Scholar
• Ortiz-masia D, Diez I, Calatayud S, et al. Induction of CD36 and thrombospondin-1 in macrophages by hypoxia-inducible factor 1 and its relevance. PLoS One. 2012;7(10):e48535. doi:10.1371/journalpone.0048535
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu J, Chen L, et al. β-patchoulene simultaneously ameliorated dextran sulfate sodius-induced colitis and secondary liver injury in rats Mice via suppressing colonic odors and flora imbalance. Biochem Pharmacol. 2020;182:114260.
   PubMed Web of Science ®Google Scholar
• Wu J, Gan Y, Luo H, et al. β-Patchoulene Ameliorates Water Transport and the Mucus Barrier in 5-Fluorouracil-Induced Intestinal Mucositis Rats via the cAMP/PKA/CREB Signaling Pathway. Front Pharmacol. 2021;12:689491. doi:10.3389/fphar.2021.689491
   PubMed Web of Science ®Google Scholar
• Luo H, Xu N, Wu J, et al. β-patchoulene protects against non-alcoholic steatohepatitis via interrupting the vicious circle among oxidative. Int Immunopharmacol. 2021;98:107915. doi:10.1016/j.intimp.2021.107915
   PubMed Web of Science ®Google Scholar
• Shirani K, Yousefsani BS, Shirani M, Karimi G. Protective effects of naringin against drugs and chemical toxins induced hepatotoxicity: a Review. Phytother Res. 2020;34(8):1734–1744. doi:10.1002/PTR.6641
   PubMed Web of Science ®Google Scholar
• Akamo AJ, Rotimi SO, Akinloye DI, et al. Naringin prevents cyclophosphamide-induced hepatotoxicity in rats by attenuating oxidative stress, fibrosis, And Inflammation. Food Chem Toxicol. 2021;153:112266. doi:10.1016/j.fct.2021.112266
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang Y, Gao W, et al. Naringin improves lipid metabolism in a tissue-engineered liver model of NAFLD and the underlying Mechanisms. Life Sci. 2021;277:119487. doi:10.1016/j.lfs.2021.119487
   PubMed Web of Science ®Google Scholar
• Yen CH, Chang HS, Yang TH, et al. High-content Screening of a Taiwanese Indigenous Plant Extract Library Identifies Syzygium Simile leaf Extract as. Int J Mol Sci. 2018. doi:10.3390/IJMS19072130
   Web of Science ®Google Scholar
• Zheng J, Li Z, Manabe Y, et al. Siphonaxanthin, a Carotenoid from Green Algae. Lipids. 2018;53(1):41–52. doi:10.1002/lipd.12002
   PubMed Web of Science ®Google Scholar
• Im AR, Kim YH, Lee HW, Song KH. Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model. J Med Food. 2016;19(5):495–503. doi:10.1089/JMF.2015.3623
   PubMed Web of Science ®Google Scholar
• Adisakwattana S. Cinnamic Acid and Its Derivatives: mechanisms for Prevention and Management of Diabetes and Its Complications. Nutrients. 2017;9(2):163. doi:10.3390/NU9020163
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun Y, Wang J, Zhou M, Wang M. Fungal Activity and Action Mechanism of Natural Product gingic Acid Against Sclerotinia l Sclerotiorum. Plant the Dis. 2019;103(5):944–950. doi:10.1094/PDIS-08-18-1355-RE
   PubMed Web of Science ®Google Scholar
• Ruwizhi N. Cinnamic Acid Derivatives and Their Biological Efficacy. Int J Mol Sci. 2020;1:548. doi:10.3390/IJMS21165712
   Web of Science ®Google Scholar
• Wu Y, Wang M, Yang T, et al. Cinnamic Acid Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Hepatic Lipogenesis and Promoting Fatty Acid Oxidation. Evid Based Complement Alternat Med. 2021;2021:1–13. doi:10.1155/201/9561613
   Web of Science ®Google Scholar
• Zhao Z, Deng ZT, Huang S, et al. Alisol B Alleviates Hepatocyte Lipid Accumulation and Lipotoxicity via Regulating RARα-PPARγ-CD36 Cascade and Attenuates Non-Alcoholic Steatohepatitis in Mice. Nutrients. 2022;14(12):2411. doi:10.3390/nu14122411
   PubMed Web of Science ®Google Scholar
• Liu L, Gao C, Yao P, Gong Z. Quercetin Alleviates High-Fat Diet-Induced Oxidized Low-Density Lipoprotein Accumulation in the Liver: implication for Autophagy Regulation. Biomed Res Int. 2015;2015:607531. doi:10.1155/2015/607531
   PubMed Web of Science ®Google Scholar
• Huang X, Chen W, Yan C, et al. Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its Progression. Biomed Pharmacother. 2019;118:109258. doi:10.1016/j.biopha.2019.109258
   PubMed Web of Science ®Google Scholar
• Liu B, Zhang J, Sun P, Yi R, Han X, Zhao X. Raw Bowl Tea (Tuocha) Polyphenol Prevention of Nonalcoholic Fatty Liver Disease by Regulating Intestinal Function in Mice. Biomolecules. 2019;9(9):435. doi:10.3390/biom9090435
   PubMed Web of Science ®Google Scholar
• Lee W, Koo HR, Choi YJ, et al. Z-ligustilide and n-Butylidenephthalide Isolated from the Aerial Parts of Angelica tenuissima Inhibit Lipid Accumulation In Vitro and In Vivo. Planta Med. 2019;85(9–10):719–728. doi:10.1055/a-0901-1307
   PubMed Web of Science ®Google Scholar
• Yang JS, Tongson J, Kim KH, Park Y. Piceatannol attenuates fat accumulation and oxidative stress in steatosis-induced HepG2 cells. Curr Res Food Sci. 2020;3:92–99. doi:10.1016/j.crfs.2020.03.008
   PubMedGoogle Scholar
• Kuo NC, Huang SY, Yang CY, Shen HH, Lee YM. Involvement of HO-1 and Autophagy in the Protective Effect of Magnolol in Hepatic Steatosis-Induced NLRP3 Inflammasome Activation In Vivo and In Vitro. Antioxidants. 2020;9(10):924. doi:10.3390/antiox9100924
   Web of Science ®Google Scholar
• Pfohl M, DaSilva NA, Marques E, et al. Hepatoprotective and anti-inflammatory effects of a standardized pomegranate (Punica granatum) fruit extract in High Fat dime-induced obesity C57BL/6 mice. Int J Food Sci Nutr. 2021;72(4):499–510. doi:10.1080/09637486.2020.1849041
   PubMed Web of Science ®Google Scholar
• Gong X, Li T, Wan R, Sha L. Cordycepin attenuates high-fat diet-induced non-alcoholic fatty liver disease via down-regulation of lipid. Int Immunopharmacol. 2021;91:107173. doi:10.1016/j.intimp.2020.107173
   PubMed Web of Science ®Google Scholar
• Kim MJ, Yoo YC, Sung NY, et al. Anti-Inflammatory Effects of Liriope platyphylla in LPS-Stimulated Macrophages and Endotoxemic Mice. Am J Chin Med. 2016;44(6):1127–1143. doi:10.1142/S0192415X16500634
   PubMed Web of Science ®Google Scholar
• Le TNH, Choi HJ, Jun HS. Ethanol Extract of Liriope platyphylla Root Attenuates non-alcoholic Fatty Liver Disease in high-fat Diet-induced obesity Mice via Regulation of Lipogenesis and Lipid Uptake. Nutrients. 2021;13(10). doi:10.3390/NU13103338
   Web of Science ®Google Scholar
• Yang Q, Shu F, Gong J, et al. Sweroside ameliorates NAFLD in high-fat diet induced obese mice through the regulation of lipid metabolism and inflammatory response. J Ethnopharmacol. 2020;255:112556. doi:10.1016/j.jep.2020.112556
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang S, Li J, et al. Effect and mechanism of ginsenoside Rg1-regulating hepatic steatosis in HepG2 cells induced by free fatty acid. Biosci Biotechnol Biochem. 2020;84(11):2228–2240. doi:10.1080/09168451.2020.1793293
   PubMed Web of Science ®Google Scholar
• Quan T, Zhou F, Chen H, et al. Ficus hirta Vahl. Ameliorates Nonalcoholic Fatty Liver Disease through Regulating Lipid Metabolism and Gut Microbiota. Oxid Med Cell Longev. 2022;2022:3474723. doi:10.1155/2022/3474723
   PubMed Web of Science ®Google Scholar
• Li Y, Jiang W, Feng Y, Wu L, Jia Y, Zhao R. Betaine Alleviates High-Fat Diet-Induced Disruption of Hepatic Lipid and Iron Homeostasis in Mice. Int J Mol Sci. 2022;23(11):6263. doi:10.3390/ijms23116263
   PubMed Web of Science ®Google Scholar
• Liao Z, Zhang J, Liu B, et al. Polysaccharide from Okra (Abelmoschus esculentus (L.) Moench) Improves Antioxidant Capacity via PI3K/AKT Pathways and Nrf2 Translocation in a Type 2 Diabetes Model. Molecules. 2019;24(10):1906. doi:10.3390/molecules24101906
   PubMed Web of Science ®Google Scholar
• Peng CH, Ker YB, Li HH, Tsou SH, Lin CL, Huang CN. Abelmoschus esculentus subfractions ameliorate hepatic lipogenesis and lipid uptake via regulating dipeptidyl peptidase-4-With improving insulin resistance. PLoS One. 2022;17(3):e0265444. doi:10.1371/journal.pone.0265444
   PubMed Web of Science ®Google Scholar
• Poornima MS, Sindhu G, Billu A, et al. Pretreatment of hydroethanolic extract of Dillenia indica L. attenuates oleic acid induced NAFLD in HepG2 cells via modulating SIRT-1/p-LKB-1/AMPK, HMGCR & PPAR-α signaling pathways. J Ethnopharmacol. 2022;292:115237. doi:10.1016/j.jep.2022.115237
   PubMed Web of Science ®Google Scholar
• Poornima MS, Sindhu G, Billu A, et al. Pretreatment of hydroethanolic extract of Dillenia indica L. attenuates oleic acid induced NAFLD in HepG2 cells via modulating SIRT-1/p-LKB-1/AMPK, HMGCR & PPAR-α signaling pathways. J Ethnopharmacol. 2022;292:115237. doi:10.1016/j.jep.2022.115237
   PubMed Web of Science ®Google Scholar
• Li CL, Liu B, Wang ZY, et al. Salvianolic acid B improves myocardial function in diabetic cardiomyopathy by suppressing IGFBP3. J Mol Cell Cardiol. 2020;139:98–112. doi:10.1016/j.yjmcc.2020.01.009
   PubMed Web of Science ®Google Scholar
• Meng LC, Zheng JY, Qiu YH, et al. Salvianolic acid B ameliorates non-alcoholic fatty liver disease by inhibiting hepatic lipid accumulation and NLRP3 inflammasome in ob/ob mice. Int Immunopharmacol. 2022;111:109099. doi:10.1016/j.intimp.2022.109099
   PubMed Web of Science ®Google Scholar
• Zhang L. Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine. Drug Deliv. 2019;26(1):860–869. doi:10.1080/10717544.2019.1660732
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang N, Aldhahrani A, Soliman MM, Zhang L, Zhou F. Puerarin ameliorates nonalcoholic fatty liver in rats by regulating hepatic lipid accumulation, oxidative stress, and inflammation. Front Immunol. 2022;13:956688. doi:10.3389/fimmu.2022.956688
   PubMed Web of Science ®Google Scholar
• Bai J, Zhang Y, Tang C, et al. Gallic acid: pharmacological activities and molecular mechanisms involved in inflammation-related diseases. Biomed Pharmacother. 2021;133:110985. doi:10.1016/j.biopha.2020.110985
   PubMed Web of Science ®Google Scholar
• Tanaka M, Sato A, Kishimoto Y, Mabashi-Asazuma H, Kondo K, Iida K. Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes. Nutrients. 2020;12(5):1479. doi:10.3390/nu12051479
   PubMed Web of Science ®Google Scholar
• Camps-Bossacoma M, Garcia-Aloy M, Saldaña-Ruiz S, et al. Role of Theobromine in Cocoa’s Metabolic Properties in Healthy Rats. J Agric Food Chem. 2019;67(13):3605–3614. doi:10.1021/acs.jafc.8b07248
   PubMed Web of Science ®Google Scholar
• Lee HW, Choi IW, Ha SK. Immunostimulatory Activities of Theobromine on Macrophages via the Activation of MAPK and NF-κB Signaling Pathways. Curr Issues Mol Biol. 2022;44(9):4216–4228. doi:10.3390/cimb44090289
   PubMed Web of Science ®Google Scholar
• Wei D, Wu S, Liu J, et al. Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro. Can J Physiol Pharmacol. 2021;99(8):775–785. doi:10.1139/cjpp-2020-0259
   PubMed Web of Science ®Google Scholar
• Ye P, Xiang M, Liao H, et al. Dual-Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression. Hepatology. 2019;69(1):76–93. doi:10.1002/hep.30198
   PubMed Web of Science ®Google Scholar
• Bou Khzam L, Son NH, Mullick AE, Abumrad NA, Goldberg IJ. Endothelial cell CD36 deficiency prevents normal angiogenesis and vascular repair. Am J Transl Res. 2020;12(12):7737–7761.
   PubMed Web of Science ®Google Scholar
• Bizzarri M, Giuliani A, Monti N, Verna R, Pensotti A, Cucina A. Rediscovery of natural compounds acting via multitarget recognition and noncanonical pharmacodynamical actions. Drug Discov Today. 2020;25(5):920–927. doi:10.1016/j.drudis.2020.02.010
   PubMed Web of Science ®Google Scholar
• Azab A, Nassar A, Azab AN. Anti-Inflammatory Activity of Natural Products. Molecules. 2016;21(10):1321. doi:10.3390/molecules21101321
   PubMed Web of Science ®Google Scholar
• Caesar LK, Cech NB. Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2. Nat Prod Rep. 2019;36(6):869–888. doi:10.1039/c9np00011a
   PubMed Web of Science ®Google Scholar